The most effective natural Back Pain treatment
Click on a box to see what we consider
the most effective natural Back Pain treatment for you

WOMEN 39
AND UNDER		 MEN 39
AND UNDER		 WOMEN 40
AND UP		 MEN 40
AND UP
click here...click here...click here...click here...

What is Back Pain?

Back pain is a common term for conditions involving pain in the back from the neck to the gluteal region (buttocks). Back pain is one of the most common medical conditions and a major reason for sick leave and early retirement. One of the main reasons for this is that therapists often overlook the fact that this condition is due to inflammation of the muscles and joints of the back in 90 percent of the cases. Patients who develop chronic inflammation and do not heal spontanously often develop back pain or similar conditions, not due to the severity of the cause/trauma, but due to insufficient amounts of anti-inflammatory and antioxidant nutrients in the body.

The fact that most people develop back pain due to a lack of natural anti-inflammatory and antioxidant nutrients in addition to essential vitamins and minerals and not due to the severity of a trauma is backed up by the most recent scientific studies (see below).

Which natural ingredients can have an effect on back pain?

Chondroitin sulfate, glucosamine sulfate, ginger root extract, fish oils (EPA/DHA), grape seed extract, green tea extract, quercetin, alpha-lipoic acid, cimicifuga racemosa (black cohosh), vitamins A, B2, B3, B6, C, D3, E and folic acid, selenium, zinc, manganese, boron, copper, magnesium, molybdenum and many more.

What effects do these ingredients have?

  • Most effective long-term analgesic (pain relieving) treatment.
  • Shorten recovery time.
  • Re-establish normal joint and muscle movement/mobility.
  • Reduce oedema.
  • Enhance the effect of physical treatment (physiotherapy, chiropractic etc).
  • Improve quality of life.
  • Relax your muscles.

For the reader with a deeper interest:

How do these ingredients work?

  • Treat and prevent vitamin and mineral deficiencies.
  • Treat the cause (inflammation) not just the symptoms.
  • Inhibit cyclooxygenase-2 (COX-2) enzymes.
  • Inhibit the breakdown of collagenase phospholipase enzymes.
  • Inhibit TNF-a and interleukin-1B.
  • Inhibit the synthesis of LB4 and prostaglandin E2.
  • With joint dislocation, the original position of the joint is re-established.
  • With protrusion of discus, original position is re-established.
  • Stop reflectory muscle spasms.
  • Normalise local blood flow.
  • No side effects.

The information above is based on more than 51,000 articles published in scientific journals and which are available at MEDLINE, the world's largest medical database. Below you will find a few of them listed:

References

  1. Adebowale, A; Du, J; Liang, Z; Leslie, JL; Eddington, ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos. 2002;23:217–225. doi: 10.1002/bdd.315. [PubMed]
  2. Antoniou, J; Steffen, T; Nelson, F; Winterbottom, N; Hollander, AP; Poole, RA; Aebi, M; Alini, M. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest. 1996;98:996–1003. [PubMed]
  3. Bali, J-P; Cousse, H; Neuzil, E. Biochemical basis of the pharmacological action of chondroitin sulfates on the osteoarticular system. Sem Arthritis Rheum. 2001;31:58–68. doi: 10.1053/sarh.2000.24874.
  4. Beren, J; Hill, SL; Diener-West, M; Rose, NR. The effect of preloading oral glucosamine/chondroitin sulfate/manganese ascorbate combination on experimental arthritis in rats. Exp Biol Med (Maywood). 2001;226:144–151. [PubMed]
  5. Boden, SD; McCowin, PR; Davis, DO; Dina, TS; Mark, AS; Wiesel, S. Abnormal magnetic-resonance scans of the cervical spine in asymptomatic subjects. A prospective investigation. J Bone Joint Surg Am. 1990;72:1178–1184. [PubMed]
  6. Canapp, SO, Jr; McLaughlin, RM, Jr; Hoskinson, JJ; Roush, JK; Butine, MD. Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate. Am J Vet Res. 1999;60:1552–1557. [PubMed]
  7. Caterson, B; Flannery, CR; Hughes, CE; Little, CB. Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000;19:333–344. doi: 10.1016/S0945-053X(00)00078-0. [PubMed]
  8. Chard, J; Dieppe, P. Glucosamine for osteoarthritis: magic, hype, or confusion? BMJ. 2001;322:1439–1440. doi: 10.1136/bmj.322.7300.1439. [PubMed]
  9. Cole, TC; Ghosh, P; Taylor, TK. Variations of the proteoglycans of the canine intervertebral disc with ageing. Biochim Biophys Acta. 1986;880:209–219. doi: 10.1016/0304-4165(86)90082-6. [PubMed]
  10. Conte, A; Volpi, N; Palmieri, L; Bahous, I; Ronca, G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittel forschung. 1995;45:918–925. [PubMed]
  11. Coventry, MB; Ghormley, RL; Kernohan, JW. The intervertebral disc: its microscopic anatomy and pathology. I. Anatomy, development and pathology. J Bone Joint Surg Am. 1945;27:105–112.
  12. Coventry, MB; Ghormley, RL; Kernohan, JW. The intervertebral disc: its microscopic anatomy and pathology. II. Changes in the intervertebral disc concomittant with age. J Bone Joint Surg Am. 1945;27:233–247.
  13. Coventry, MB; Ghormley, RL; Kernohan, JW. The intervertebral disc: its microscopic anatomy and pathology. III. Pathologic changes in the intervertebral disc. J Bone Joint Surg Am. 1945;27:460–474.
  14. Das, A, Jr; Hammad, TA. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage. 2000;8:343–350. doi: 10.1053/joca.1999.0308. [PubMed]
  15. De los Reyes, GC; Koda, RT; Lien, EJ. Glucosamin and chondroitin sulfates in the treatment of osteoarthritis: a survey. Prog Drug Res. 2000;55:81–103. [PubMed]
  16. Deal, CL; Moskowitz, RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am. 1999;25:379–395. [PubMed]
  17. Drovanti, A; Bignamini, AA; Rovati, AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: A placebo-controlled double-blind investigation. Clin Therapeutics. 1980;3:260–272.
  18. Echard, BW; Talpur, NA; Funk, KA; Bagchi, D; Preuss, HG. Effects of oral glucosamine and chondroitin sulfate alone and in combination on the metabolism of SHR and SD rats. Mol Cell Biochem. 2001;225:85–91. doi: 10.1023/A:1012225025475. [PubMed]
  19. Elfering, A; Semmer, N; Birkhofer, D; Zanetti, M; Hodler, J; Boos, N. Risk factors for lumbar disk degeneration: a 5-year prospective MRI study in asymptomatic individuals. Spine. 2002;27:125–134. doi: 10.1097/00007632-200201150-00002. [PubMed]
  20. Fenton, JI; Chlebek-Brown, KA; Peters, TL; Caron, JP; Orth, MW. Glucosamine-HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage. 2000;8:258–265. doi: 10.1053/joca.1999.0299. [PubMed]
  21. Furderer, S; Wenda, K; Thiem, N; Hachenberger, R; Eysel, P. Traumatic intervertebral disc lesion-magnetic resonance imaging as a criterion for or against intervertebral fusion. Eur Spine J. 2001;10:154–163. doi: 10.1007/s005860000238. [PubMed]
  22. Goupille, P; Jayson, MI; Valat, JP; Freemont, AJ. Matrix metalloproteinases: the clue to intervertebral disc degeneration? Spine. 1998;23:1612–1626. doi: 10.1097/00007632-199807150-00021. [PubMed]
  23. Gouze, JN; Bordji, K; Gulberti, S; Terlain, B; Netter, P; Magdalou, J; Fournel-Gigleux, S; Ouzzine, M. Interleukin-1beta downregulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum. 2001;44:351–360. doi: 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.3.CO;2-D. [PubMed]
  24. Greenwood J. Optimum vitamin C intake as a factor in the preservation of disc integrity. Med Ann District of Columbia 1964;33:274–6.
  25. Hayes, AJ; Benjamin, M; Ralphs, JR. Extracellular matrix in development of the intervertebral disc. Matrix Biol. 2001;20:107–121. doi: 10.1016/S0945-053X(01)00125-1. [PubMed]
  26. Heinegard, D; Oldberg, A. Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J. 1989;3:2042–2051. [PubMed]
  27. Horner, HA; Urban, JP. 2001 Volvo Award Winner in Basic Science Studies: Effect of nutrient supply on the viability of cells from the nucleus pulposus of the intervertebral disc. Spine. 2001;26:2543–2549. doi: 10.1097/00007632-200112010-00006. [PubMed]
  28. Johnstone, B; Blayliss, MT. The large proteoglycans of the human intervertebral disc: Changes in their biosynthesis and structure with age, topography and pathology. Spine. 1995;20:674–684. [PubMed]
  29. Kang, JD; Stefanovic-Racic, M; McIntyre, LA; Georgescu, HI; Evans, CH. Toward a biochemical understanding of human intervertebral disc degeneration and herniation. Contributions of nitric oxide, interleukins, prostaglandin E2, and matrix metalloproteinases. Spine. 1997;22:1065–1073. doi: 10.1097/00007632-199705150-00003. [PubMed]
  30. Leeb, BF; Petera, P; Neumann, K. Results of a multicenter study of chondroitin sulfate use in arthroses of the finger, knee and hip joints. Wien Med Wochenschr. 1996;146:609–614. [PubMed]
  31. Leeb, BF; Schweitzer, H; Montag, K; Smolen, JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol. 2000;27:205–211. [PubMed]
  32. Leffler, CT; Philippi, AF; Leffler, SG; Mosure, JC; Kim, PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee, or low back: A randomized, double-blind, placebo-controlled pilot study. Mil Med. 1999;164:85–91. [PubMed]
  33. Lippiello, L; Woodward, J; Karpman, R; Hammad, TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop. 2000;381:229–240. [PubMed]
  34. Lyons, G; Eisenstein, SM; Sweet, MB. Biochemical changes in intervertebral disc degeneration. Biochim Biophys Acta. 1981;673:443–453. doi: 10.1016/0304-4165(81)90476-1. [PubMed]
  35. McAlindon, T. Glucosamin for osteoarthritis: dawn of a new era? Lancet. 2001;357:247–248. doi: 10.1016/S0140-6736(00)03606-0. [PubMed]
  36. McAlindon, TE; La Valley, MP; Gulin, JP; Felson, DT. Glucosamine and chondroitin for treatment of osteoarthritis. A systematic Quality assessment and meta-analysis. JAMA. 2000;283:1469–1475. doi: 10.1001/jama.283.11.1469. [PubMed]
  37. Miller, JA; Schmatz, C; Schultz, AB. Lumbar disc degeneration: correlation with age, sex, and spine level in 600 autopsy specimens. Spine. 1988;13:173–178. [PubMed]
  38. Modic, MT; Pavlicek, W; Weinstein, MA; Boumphrey, F; Ngo, F; Hardy, R; Duchesneau, PM. Magnetic resonance imaging of intervertebral disk disease. Clinical and pulse sequence considerations. Radiology. 1984;152:103–111. [PubMed]
  39. Nachemson, A; Lewin, T; Maroudas, A; Freeman, MA. In vitro diffusion of dye through the end-plates and annulus fibrosis of human lumbar intervertebral discs. Acta Orthop Scand. 1970;41:589–607. [PubMed]
  40. Noyszewski, EA; Wroblewski, K; Dodge, GR; Kudchodkar, S; Beers, J; Sarma, AV; Reddy, R. Preferential incorporation of glucosamine into galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum. 2001;44:1089–1095. doi: 10.1002/1529-0131(200105)44:5<1089::AID-ANR189>3.3.CO;2-0. [PubMed]
  41. Oegema, TR, Jr; Deloria, LB; Sandy, JD; Hart, DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum. 2002;46:2495–2503. doi: 10.1002/art.10499. [PubMed]
  42. Ogata, K; Whiteside, LA. Nutrition pathway of the intervertebral disc. Spine. 1981;6:211–216. [PubMed]
  43. Okuda, S; Myoui, A; Ariga, K; Nakase, T; Yonenobu, K; Yoshikawa, H. Mechanisms of age-related decline in insulin-like growth factor-I dependent proteoglycan synthesis in rat intervertebral disc cells. Spine. 2001;26:2421–2426. doi: 10.1097/00007632-200111150-00005. [PubMed]
  44. Omata, T; Segawa, Y; Itokazu, Y; Inoue, N; Tanaka, Y. Effects of chondroitin sulfate-C on bradykinin-induced proteoglycan depletion in rats. Arzneimittel forschung. 1999;49:577–581. [PubMed]
  45. Orth, MW; Peters, TL; Hawkins, JN. Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine vet J Suppl. 2002;34:224–229. [PubMed]
  46. Pearce, RH; Grimmer, BJ; Adams, ME. Degeneration and the chemical composition of the human intervertebral disk. J Orthop Res. 1987;5:198–205. [PubMed]
  47. Plaas, AHK; West, LA; Wong-Palms, S; Nelson, FRT. Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate. J Biol Chem. 1998;273:12642–12649. doi: 10.1074/jbc.273.20.12642. [PubMed]
  48. Reginster, JY; Deroisy, R; Rovati, LC; Lee, RL; Lejeune, E; Bruyere, O; Giacovelli, G; Henrotin, Y; Dacre, JE; Gossett, C. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357:251–256. doi: 10.1016/S0140-6736(00)03610-2. [PubMed]
  49. Reyentovich, A; Abdu, WA. Multiple independent, sequential, and spontaneously resolving lumbar intervertebral disc herniations: a case report. Spine. 2002;27:549–553. doi: 10.1097/00007632-200203010-00024. [PubMed]
  50. Roberts, S; Caterson, B; Menage, J; Evans, EH; Jaffray, DC; Eisenstein, SM. Matrix metalloproteinases and aggrecanase: their role in disorders of the human intervertebral disc. Spine. 2000;25:3005–3013. doi: 10.1097/00007632-200012010-00007. [PubMed]
  51. Ronca, G; Conte, A. Metabolic fate of partially depolymerized shark chondroitin sulfate in man. Int J Clin Pharmacol Res. 1993;13:27–34. [PubMed]
  52. Sandy, JD; Gamett, D; Thompson, V; Verscharen, C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J. 1998;335:59–66. [PubMed]
  53. Schwartz, NB; Dorfman, A. Stimulation of chondroitin sulfate proteoglycan production by chondrocytes in monolayer. Connect Tissue Res. 1975;3:115–122. [PubMed]
  54. Schwieger G, Karl H, Schonhaber E. Relapse prevention of painful vertebral syndromes in follow-up treatment with a combination of vitamins B1, B6, and B12. Ann NY Acad Sci 1990;585:54–62.
  55. Setnikar, I; Rovati, LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittel forschung. 2001;51:699–725. [PubMed]
  56. Shikhman, AR; Kuhn, K; Alaaeddine, N; Lotz, M. N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol. 2001;166:5155–5160. [PubMed]
  57. Sugahara, K; Kitagawa, H. Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. Curr Opin Struct Biol. 2000;10:518–527. doi: 10.1016/S0959-440X(00)00125-1. [PubMed]
  58. Taylor, TK; Melrose, J; Burkhardt, D; Ghosh, P; Claes, LE; Kettler, A; Wilke, HJ. Spinal biomechanics and aging are major determinants of the proteoglycan metabolism of intervertebral disc cells. Spine. 2000;25:3014–3020. doi: 10.1097/00007632-200012010-00008. [PubMed]
  59. Towheed, TE; Anastassiades, TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis. Evidence is widely touted but incomplete. JAMA. 2000;283:1483–1484. doi: 10.1001/jama.283.11.1483. [PubMed]
  60. Towheed, TE; Anastassiades, TP; Shea, B; Houpt, J; Welch, V; Hochberg, MC. Glucosamine therapy for treating osteoarthritis (Cochrane Review). Cochrane Database Syst Rev. 2001;1:CD002946. [PubMed]
  61. Uebelhart, D; Thonar, EJ; Zhang, J; Williams, JM. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthritis Cartilage. 1998;6:6–13. [PubMed]
  62. Verbruggen, G; Goemaere, S; Veys, EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002;21:231–343. doi: 10.1007/s10067-002-8290-7. [PubMed]
  63. Volpi, N. Oral bioavailability of chondroitin sulfate (Condrosulf((R)) and its constituents in healthy male volunteers. Osteoarthritis Cartilage. 2002;10:768–771. doi: 10.1053/joca.2002.0824. [PubMed]
  64. Weiler, C; Nerlich, AG; Zipperer, J; Bachmeier, BE; Boos, N. 2002 SSE Award Competition in Basic Science: Expression of major matrix metalloproteinases is associated with intervertebral disc degradation and resorption. Eur Spine J. 2002;11:308–320. doi: 10.1007/s00586-002-0472-0. [PubMed]
  65. Williams, A; Oppenheimer, RA; Gray, ML; Burstein, D. Differential recovery of glycosaminoglycan after IL-1-induced degradation of bovine articular cartilage depends on degree of degradation. Arthritis Res Ther. 2003;5:R97–R105. doi: 10.1186/ar615. [PubMed]